Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery
| العنوان: | Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery |
|---|---|
| المؤلفون: | Mitsune Tanimoto, Isao Oze, Kadoaki Ohashi, Toshio Kubo, Junichi Soh, Shinichi Toyooka, Go Makimoto, Masahiro Tabata, Kuniaki Katsui, Katsuyuki Kiura, Katsuyuki Hotta, Nagio Takigawa |
| المصدر: | Japanese Journal of Clinical Oncology. 48:287-290 |
| بيانات النشر: | Oxford University Press (OUP), 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Adult, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, animal structures, Population, 03 medical and health sciences, 0302 clinical medicine, Cancer Survivors, Carcinoma, Non-Small-Cell Lung, Humans, Medicine, Radiology, Nuclear Medicine and imaging, education, Lung cancer, Prospective cohort study, Survival rate, Aged, Neoplasm Staging, education.field_of_study, Cancer survivor, business.industry, Standard treatment, Incidence (epidemiology), fungi, Neoplasms, Second Primary, Chemoradiotherapy, General Medicine, Middle Aged, medicine.disease, Surgery, Survival Rate, Treatment Outcome, 030228 respiratory system, Oncology, 030220 oncology & carcinogenesis, Female, business |
| الوصف: | The standard treatment for patients with locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT), but surgical resection following induction CRT can extend overall survival in a select population. However, patients who survive longer are at risk of developing a second primary cancer (SPC). This is the first report to determine the incidence of SPC in survivors with LA-NSCLC after trimodal therapy. Between October 1997 and October 2013, 112 Stage III NSCLC patients underwent trimodal therapy in our hospital. The 5-year overall survival rate was 71.8%. SPC developed in 10 of the 112 patients 0.60-15.0 (median 5.49) years after initiating CRT. The observed incidence of SPC was 1.8 per 100 patient-years. Although trimodal therapy can prolong patient survival, the estimated incidence of SPC does not increase. A large prospective study with a longer follow-up time is required to determine the effects of trimodal therapy, including the development of SPC. |
| تدمد: | 1465-3621 0368-2811 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::254588078e8f7b76117b5b380060000fTest https://doi.org/10.1093/jjco/hyy003Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....254588078e8f7b76117b5b380060000f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14653621 03682811 |
|---|